/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. OncLive® On Air
  2. S18 Ep51: Subcutaneous Therapies Bolster Administration Options in Multiple Myeloma
S18 Ep51: Subcutaneous Therapies Bolster Administration Options in Multiple Myeloma

S18 Ep51: Subcutaneous Therapies Bolster Administration Options in Multiple Myeloma

OncLive® On Air · Sep 30, 2026

On-body injectors for myeloma drugs like isatuximab reduce administration burdens and nearly eliminate infusion reactions (25% to 1.5%).

On-Body Injectors Free Oncology Nurses from Being "Tethered" to the Patient's Bedside

Manual subcutaneous pushes require nurses to be physically present, applying constant pressure for several minutes. On-body systems automate this, untethering nurses to attend to other patients or tasks. This improves clinic workflow efficiency and reduces the physical strain and professional burden on nursing staff.

S18 Ep51: Subcutaneous Therapies Bolster Administration Options in Multiple Myeloma thumbnail

S18 Ep51: Subcutaneous Therapies Bolster Administration Options in Multiple Myeloma

OncLive® On Air·2 months ago

On-Body Injectors Pave the Way for At-Home Myeloma Therapy Administration

The development of on-body delivery systems for complex biologics is more than an incremental improvement. It represents a crucial technological step toward moving cancer care from the clinic into a patient's home, a long-sought goal that could dramatically increase patient convenience and access to care.

S18 Ep51: Subcutaneous Therapies Bolster Administration Options in Multiple Myeloma thumbnail

S18 Ep51: Subcutaneous Therapies Bolster Administration Options in Multiple Myeloma

OncLive® On Air·2 months ago

Near-Elimination of Infusion Reactions Transforms New Patient Onboarding Experience

The drop in systemic administration reactions from 25% (IV) to 1.5% (on-body injector) is a "game changer." It shifts the initial conversation with new patients from managing fear about a common, scary reaction to focusing on the treatment's benefits, improving the psychological start to therapy.

S18 Ep51: Subcutaneous Therapies Bolster Administration Options in Multiple Myeloma thumbnail

S18 Ep51: Subcutaneous Therapies Bolster Administration Options in Multiple Myeloma

OncLive® On Air·2 months ago

Drug Delivery Innovation Requires Proving Both Efficacy and Pharmacokinetic Non-Inferiority

Gaining FDA approval for a new delivery system like an on-body injector requires more than showing it works. The Iroclia trial for subcutaneous isatuximab had to meet dual primary endpoints, proving non-inferiority in both clinical efficacy (response rates) and pharmacokinetics (drug levels in the blood), setting a high regulatory bar.

S18 Ep51: Subcutaneous Therapies Bolster Administration Options in Multiple Myeloma thumbnail

S18 Ep51: Subcutaneous Therapies Bolster Administration Options in Multiple Myeloma

OncLive® On Air·2 months ago